

PA24 Yescarta™ (axicabtagene ciloleucel) or Kymriah® (tisagenlecleucel)

## **Executive Office of Health & Human Services**

MEDICAID FEE FOR SERVICE (FFS) PRIOR AUTHORIZATION REQUEST FORM Gainwell Technologies ATTN: PHARMACIST FAX (401) 784-3889 • PH (401) 784-8100

NAME:DOB:/ID NUMBE	-n.
BER NAME:PRESCRIBER NPI #:	
PHONE NUMBER: ( )OFFICE FAX NUMBER: ( )	
ING PROVIDER NAME: RENDERING PROVIDER NPI #:	
PORTING DOCUMENTATION SHOULD BE MAINTAINED WITH THE PATIENT RECORD. ADD SHOULD BE SUBMITTED ONLY IF REQUESTED BY RI EOHHS.	OITIONAL DOCUMENTATION
LINFORMATION:	
CAR T REQUESTED (SELECT ONE): KYMRIAH® (tisagenlecleucel) Q2040 orYESCARTA™ (a	(axicabtagene ciloleucel) Q2041
REQUESTED DATE OF TREATMENT:	
DIAGNOSIS:ICD	10 CODE:
CURRENT CLINICAL STATUS:	
HAS THE PATIENT HAD PRIOR THERAPY WITH GENE THERAPY:	YESNO
HAS THE PATIENT FAILED AT LEAST TWO LINES OF THERAPY?	YES NO
IS THE PATIENT'S DISEASE REFRACTORY, OR HAS THE PATIENT RELAPSED AFTER 2 OR MORE LINES OF THERAPY	
DOES THE PATIENT HAVE PRIOR CENTRAL NERVOUS SYSTEM LYMPHOMA:	YES NC
DOES THE PATIENT HAVE ADEQUATE BONE MARROW, CARDIAC, PULMONARY AND OTHER ORGAN FUNCTION:	
DOES THE PATIENT HAVE A HISTORY OF ALLOGENIC STEM CELL TRANSPLANTATION:	YESNC
i. <u>IF YES</u> , IS THERE ANY INDICATION OF GRAFT VS HOST DISEASE:	YESNC
IS RENDERING PROVIDER/FACILITY CERTIFIED UNDER KYMRIAH® OR YESCARTA™ REMS SYSTEM PROGRAM:	YES NC
BER ATTESTATION AND SIGNATURE	_DATE
IGNATURE, THE PRESCRIBER CONFIRMS S/HE IS AUTHORIZED TO PRESCRIBE THIS MEDICATION BY RI MEDICAID ABOVE IS ACCURATE, VERIFIABLE BY CLIENT RECORDS AND AVAILABLE FOR REVIEW UPON I	
PH III	HONE NUMBER: ( )